key: cord-0848372-0oe5ncwe
authors: Horby, P. W.; Mafham, M.; Peto, L.; Campbell, M.; Pessoa-Amorim, G.; Spata, E.; Staplin, N.; Emberson, J. R.; Prudon, B.; Hine, P.; Brown, T.; Green, C. A.; Sarkar, R.; Desai, P.; Yates, B.; Bewick, T.; Tiberi, S.; Felton, T.; Baillie, J. K.; Buch, M. H.; Chappell, L. C.; Day, J. N.; Faust, S. N.; Jaki, T.; Jeffery, K.; Juszczak, E.; Lim, W. S.; Montgomery, A.; Mumford, A.; Rowan, K.; Thwaites, G.; Weinreich, D. M.; Haynes, R.; Landray, M. J.
title: Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
date: 2021-06-16
journal: nan
DOI: 10.1101/2021.06.15.21258542
sha: 2bdb5ab70210838f02bd385db7735ec021c9bb1b
doc_id: 848372
cord_uid: 0oe5ncwe

Background: REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of REGEN-COV in patients admitted to hospital with COVID-19. Methods: In this randomised, controlled, open-label platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus a single dose of REGEN-COV 8g (casirivimab 4g and imdevimab 4g) by intravenous infusion (REGEN-COV group). The primary outcome was 28-day mortality assessed first among patients without detectable antibodies to SARS-CoV-2 at randomisation (seronegative) and then in the overall population. Findings: Between 18 September 2020 and 22 May 2021, 9785 patients were randomly allocated to receive usual care plus REGEN-COV or usual care alone, including 3153 (32%) seronegative patients, 5272 (54%) seropositive patients and 1360 (14%) patients with unknown baseline antibody status. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to REGEN-COV and 451 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio 0.80; 95% CI 0.70-0.91; p=0.0010). In an analysis involving all randomised patients (regardless of baseline antibody status), 944 (20%) of 4839 patients allocated to REGEN-COV and 1026 (21%) of 4946 patients allocated to usual care died within 28 days (rate ratio 0.94; 95% CI 0.86-1.03; p=0.17). The proportional effect of REGEN-COV on mortality differed significantly between seropositive and seronegative patients (p value for heterogeneity = 0.001). Interpretation: In patients hospitalised with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab (REGEN-COV) reduced 28-day mortality among patients who were seronegative at baseline.

Monoclonal antibodies (mAbs) are a set of identical antibodies that have high specificity 56 and affinity for a single epitope. They have been demonstrated to be safe and effective in 57 Regeneron Pharmaceuticals (Tarrytown, New York, USA) has developed two non-73 competing, high-affinity human IgG1 anti-SARS-CoV-2 mAbs, casirivimab and 74 imdevimab, which bind specifically to the receptor binding domain of the spike 75 glycoprotein of SARS-CoV-2, blocking viral entry into host cells. 13 A combination of 76 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2021. ; https://doi.org/10.1101/2021.06.15.21258542 doi: medRxiv preprint antibodies that bind to non-overlapping epitopes, rather than a single antibody, is 77 intended to minimize the likelihood of loss of antiviral activity due to naturally circulating 78 viral variants or development of escape mutants under drug pressure. 14 However, to date, no virus-directed therapy has been shown to reduce mortality in 93 hospitalised patients with COVID-19, for whom the only treatments so far shown to reduce 94 mortality have been those that modify the inflammatory response. [20] [21] [22] . The only published 95 trial of an anti-spike mAb (bamlanivimab) in hospitalised patients was terminated for 96 futility after 314 patients had been randomised. 23, 24 Two other studies of mAb products 97 (VIR-7831 monotherapy, and BRII-196 with BRII-198 combination therapy) in 98 hospitalized COVID-19 patients were also terminated for futility with sample sizes of 344 99

Baseline presence of anti-SARS-CoV-2 antibodies was to be determined for each 143 participant using serum samples taken at the time of randomisation. Analysis was done 144 at a central laboratory with a validated 384 well plate indirect ELISA for anti-spike IgG 145 (appendix p 28). 31 Participants were categorised as seropositive or seronegative using a 146 predefined assay threshold with a 99% or higher sensitivity and specificity in detecting 147 individuals with SARS-CoV-2 infection at least 20 days previously. 31 148

Eligible and consenting patients were assigned in a 1:1:1 ratio to either usual standard of 149 care, usual standard of care plus REGEN-COV or usual standard of care plus 150 convalescent plasma (until 15 January 2021), using web-based simple (unstratified) 151 randomisation with allocation concealed until after randomisation (appendix pp 32-33). 152

For some patients, REGEN-COV was unavailable at the hospital at the time of enrolment 153 or was considered by the managing physician to be either definitely indicated or definitely 154 contraindicated. These patients were excluded from the randomised comparison between 155 REGEN-COV and usual care. Patients allocated to REGEN-COV were to receive a single 156 dose of REGEN-COV 8g (casirivimab 4g and imdevimab 4g) in 250ml 0.9% saline infused 157 intravenously over 60 minutes +/-15 minutes as soon as possible after randomisation. 158

As a platform trial, and in a factorial design, patients could be simultaneously randomised 159 to other treatment groups: i) azithromycin versus usual care, ii) colchicine versus usual 160 care, iii) aspirin versus usual care, and iv) baricitinib versus usual care. Further details of 161 when these factorial randomisations were open is provided in the supplementary 162 appendix (pp 32-33). Until 24 January 2021, the trial also allowed a subsequent 163 randomisation for patients with progressive COVID-19 (evidence of hypoxia and a hyper-164 inflammatory state) to tocilizumab versus usual care. Participants and local study staff 165 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) were not masked to the allocated treatment. The trial steering committee, investigators, 166 and all other individuals involved in the trial were masked to outcome data during the trial. 167

Early safety outcomes were recorded by site staff using an online form 72 hours after 169 randomisation (appendix pp 37-41). An online follow-up form was completed by site staff 170 when patients were discharged, had died, or at 28 days after randomisation, whichever 171 occurred first (appendix pp 42-48). Information was recorded on adherence to allocated 172 trial treatment, receipt of other COVID-19 treatments, duration of admission, receipt of 173 respiratory or renal support, and vital status (including cause of death). In addition, routine 174 health-care and registry data were obtained, including information on vital status at day 175 28 (with date and cause of death); discharge from hospital; and receipt of respiratory 176 support or renal replacement therapy. 177

Outcomes were assessed at 28 days after randomisation, with further analyses specified 179 at 6 months. The primary outcome was 28-day all-cause mortality. Secondary outcomes 180 were time to discharge from hospital, and, among patients not on invasive mechanical 181 ventilation at randomisation, the composite outcome of invasive mechanical ventilation 182 (including extra-corporeal membrane oxygenation) or death. Prespecified subsidiary 183 clinical outcomes were use of invasive or non-invasive ventilation among patients not on 184 any ventilation at randomisation, time to successful cessation of invasive mechanical 185 ventilation (defined as cessation of invasive mechanical ventilation within, and survival to, 186 28 days), and use of renal dialysis or haemofiltration. Information on suspected serious 187 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

For all outcomes, intention-to-treat analyses compared patients randomised to COV with patients randomised to usual care but for whom REGEN-COV was both 199 available and suitable as a treatment. For the primary outcome of 28-day mortality, the 200 log-rank observed minus expected statistic and its variance were used to both test the 201 null hypothesis of equal survival curves (i.e., the log-rank test) and to calculate the one-202 step estimate of the average mortality rate ratio. We constructed Kaplan-Meier survival 203 curves to display cumulative mortality over the 28-day period. 204

For this preliminary report, information on the primary outcome is available for 99% of 205 randomised patients. Those patients who had not been followed for 28 days and were not 206 known to have died by the time of the data cut for this preliminary analysis (25 May 2021) 207

were either censored on 25 May 2021 or, if they had already been discharged alive, were 208 right-censored for mortality at day 29 (that is, in the absence of any information to the 209 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 16, 2021. ; contrary they were assumed to have survived 28 days). [Note: This censoring rule will not 210 be necessary when all patients have completed the 28 day follow-up period on 19 June 211

We used the same method to analyse time to hospital discharge and successful cessation 213 of invasive mechanical ventilation, with patients who died in hospital right-censored on 214 day 29. Median time to discharge was derived from Kaplan-Meier estimates. For the pre-215 specified composite secondary outcome of progression to invasive mechanical ventilation 216 or death within 28 days (among those not receiving invasive mechanical ventilation at 217 randomisation), and the subsidiary clinical outcomes of receipt of ventilation and use of 218 haemodialysis or haemofiltration, the precise dates were not available and so the risk 219 ratio was estimated instead. Estimates of rate and risk ratios (both denoted RR) are 220

shown with 95% confidence intervals. 221

In the light of new evidence which became available during the trial, it was hypothesised 222 that any beneficial effect of REGEN-COV would be larger among seronegative 223 participants (and may be negligible in seropositive participants). 15,19 Consequently, prior 224 to any unblinding of results, the trial steering committee specified that hypothesis-testing 225 of the effect of allocation to REGEN-COV on 28-day mortality (and secondary outcomes) 226 would first be done only in seronegative participants (appendix pp. 142-144). Hypothesis 227 testing of the primary outcome among all randomised patients was then only to be done 228 if a reduction in mortality in seronegative patients was seen at 2P<0.05. A prespecified 229 comparison of the effects of allocation to REGEN-COV on 28-day mortality in 230 seronegative versus seropositive participants was done by performing a test for 231 heterogeneity. Tests for heterogeneity according to other baseline characteristics (age, 232 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2021. ; https://doi.org/10.1101/2021.06.15.21258542 doi: medRxiv preprint sex, ethnicity, level of respiratory support, days since symptom onset, and use of 233 corticosteroids) (appendix p 133-134) were also prespecified. 234

The full database is held by the study team which collected the data from study sites and 235

performed the analyses at the Nuffield Department of Population Health, University of 236

Oxford (Oxford, UK). 237

As stated in the protocol, appropriate sample sizes could not be estimated when the trial 238 was being planned at the start of the COVID-19 pandemic. On 27 April 2021, the trial 239 steering committee, whose members were unaware of the results of the trial comparisons, in the trial were masked to outcome data until after the close of recruitment (appendix p 247

Analyses were performed using SAS version 9.4 and R version 4.0.3. The trial is 249 registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936). 250

The funder of the study had no role in study design, data collection, data analysis, data 252 interpretation, or writing of the report. Regeneron Pharmaceuticals supported the study 253 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In both the seronegative patients and in all patients combined, the proportional effects on 290 mortality seen in the respective populations were consistent across all other pre-specified 291 subgroups (webfigure 1 and webfigure 2). Results were virtually identical when restricted 292 to participants with a positive SARS-CoV-2 PCR test (webtable 5). In a sensitivity analysis 293 using a Cox model adjusted for all pre-specified subgroups, allocation to REGEN-COV 294 was associated with a mortality rate ratio of 0·85 (95% CI 0·74-0·98) in seronegative 295 patients (webtable 5). Among all participants, there was no evidence that the effect on 296 mortality varied depending on concurrent randomised allocation to azithromycin, 297 colchicine, or aspirin (all interaction p-values >0.1). 298 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2021. 4 and figure 3) . 310

There was clear evidence that the proportional effects on each of these secondary 311 outcomes differed significantly between seropositive and seronegative patients (p value 312 for heterogeneity both <0.001) (figure 3). There was no good evidence of differences in 313 treatment effect in other subgroups of patients (webfigures 4 and 5). 314

Among seronegative patients, allocation to REGEN-COV versus usual care was 315 associated with less frequent progression to use of ventilation among patients not on such 316 treatment at baseline versus usual care (28% vs 32%; risk ratio 0·87, 95% CI 0·77 to 317 0·98) (table 2) but not in the overall study population (23% vs. 24%; risk ratio 0·95, 95% 318 CI 0·87 to 1·04) (webtable 4). There were no meaningful differences in progression to 319 renal replacement therapy, non-COVID mortality, cardiac arrhythmia, thrombosis or major 320 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In this large, randomised trial, allocation to REGEN-COV in patients who were anti-SARS-334

CoV-2 antibody negative at randomisation significantly reduced 28-day mortality by about 335 one-fifth, an absolute benefit of 6 fewer deaths per 100 patients allocated REGEN-COV. 336

In addition, allocation to REGEN-COV was associated with an increased rate of discharge 337 alive from hospital within the first 28 days and a reduced rate of progression to invasive 338 mechanical ventilation or death in these patients. By contrast, no such benefits were seen 339 for patients who were anti-SARS-CoV-2 antibody positive at randomisation. 340

Consequently, when all patients were considered together (including those with unknown 341 antibody status), allocation to REGEN-COV was associated with non-significant 342 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Strengths of this trial included that it was randomised, had a large sample size, broad 380 eligibility criteria and more than 99% of patients were followed up for the primary outcome. 381

Information on virological outcomes was not collected, nor was information on radiological 382 or physiological outcomes. Although this randomised trial is open label (i.e., participants 383 and local hospital staff are aware of the assigned treatment), the outcomes are 384 unambiguous and were ascertained without bias through linkage to routine health 385 records. The dose of REGEN-COV used in this study was high compared to those used 386 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. study materials are available online at www.recoverytrial.net. As described in the protocol, 432 the trial Steering Committee will facilitate the use of the study data and approval will not 433 be unreasonably withheld. Deidentified participant data will be made available to bona 434 fide researchers registered with an appropriate institution within 3 months of publication. 435

However, the Steering Committee will need to be satisfied that any proposed publication 436

is of high quality, honours the commitments made to the study participants in the consent 437 documentation and ethical approvals, and is compliant with relevant legal and regulatory 438 requirements (e.g. relating to data protection and privacy). The Steering Committee will 439 have the right to review and comment on any draft manuscripts prior to publication. Data 440 will be made available in line with the policy and procedures described at: CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2021. ; https://doi.org/10.1101/2021.06.15.21258542 doi: medRxiv preprint

Above all, we would like to thank the thousands of patients who participated in this trial. 449

We would also like to thank the many doctors, nurses, pharmacists, other allied health Data are n (%). median (IQR) or n/N (%). RR=rate ratio for the outcomes of 28-day mortality, hospital discharge, and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes. * Analyses exclude those on invasive mechanical ventilation at randomisation. † Analyses exclude those on invasive or non-invasive ventilation at randomisation. ‡ Analyses exclude those not receiving invasive mechanical ventilation at randomisation. § Analyses exclude those on renal replacement therapy at randomisation.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 16, 2021. ; https://doi.org/10.1101/2021.06.15.21258542 doi: medRxiv preprint

How can monoclonal antibodies be harnessed against neglected 476 tropical diseases and other infectious diseases?

Ebola Virus Disease Therapeutics

Humanized Respiratory Syncytial Virus Monoclonal Antibody

Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

Human neutralizing antibodies against SARS-484

CoV-2 require intact Fc effector functions for optimal therapeutic protection

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Human neutralizing antibodies elicited by SARS-CoV-490 2 infection

A human monoclonal antibody blocking SARS-492

CoV-2 infection

Cross-neutralization of SARS-CoV-2 by a 494 human monoclonal SARS-CoV antibody

Potently neutralizing and protective human 496 antibodies against SARS-CoV-2

A human neutralizing antibody targets the receptor-498 binding site of SARS-CoV-2

Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B 501 Cells

REGN-COV2 antibodies prevent and treat 503 SARS-CoV-2 infection in rhesus macaques and hamsters

Studies in humanized mice and 506 convalescent humans yield a SARS-CoV-2 antibody cocktail

Antibody cocktail to SARS-CoV-2 spike 508 protein prevents rapid mutational escape seen with individual antibodies

REGN-COV2, a Neutralizing 511 Antibody Cocktail, in Outpatients with Covid-19

Cocktail Clinical Outcomes Study in Covid-19 Outpatients

Effect of Bamlanivimab as Monotherapy or in 516

Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-517 19: A Randomized Clinical Trial

SARS-CoV-2 Neutralizing Antibody LY-CoV555 519 in Outpatients with Covid-19

Seronegative 396/1633 (24%) 451/1520 (30%)

Number eligible for randomisation to REGEN−COV n=11464 (47%)

Total recruited * n=24343 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 16, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted June 16, 2021. ; https://doi.org/10.1101/2021.06.15.21258542 doi: medRxiv preprint